TORONTO, May 2 /PRNewswire-FirstCall/ - GeneNews Limited , a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today reported operational and financial results for the first quarter ended March 31, 2008.
“During the quarter, we achieved several of the key milestones necessary to support the commercialization of our first product, ColonSentry(TM), a risk stratification test for colorectal cancer,” said Dr. K. Wayne Marshall, President and CEO of GeneNews. “We remain on track to launch the laboratory-developed test (LDT) version of ColonSentry(TM) in the third quarter of 2008. The test will be administered as a service by our in-house clinical reference lab located at our headquarters just north of Toronto, Canada. This novel test will initially target the estimated 1.5 million people over the age of 50 in the Greater Toronto Area who should be screened for colorectal cancer, the vast majority of whom do not currently comply with screening guidelines.”
Financial results (CDN dollars) for the first quarter, ended March 31, 2008:
Total revenue for the first quarter was $0.3 million compared to $1.7 million for the same period last year. Revenue in the first quarter of 2008 resulted from a collaboration agreement entered into with an Asian biomedical consortium to identify and validate a set of biomarkers in the field of prostate diseases, for a total fee of $2 million (USD), while revenue in 2007 resulted from a collaboration agreement with Pfizer completed in the first fiscal quarter of 2007.
Total operating expenditures for the first quarter were $2.9 million compared with $3.5 million for the same period last year. Research and development expenses for the first quarter were $2.2 million compared with $2.7 million for the same period last year. General and administrative expenses for the first quarter were $0.5 million compared with $0.6 million for the corresponding quarter in the previous year.
The net loss for the first quarter was $2.6 million or a loss of $0.05 per common share compared with a net loss of $1.7 million or a loss of $0.03 per common share for the same period last year. The net loss is reflective of the Company’s continuing focus on research and development and product development leading to commercialization of its first product, ColonSentry(TM), and the advancement of related products in the Company’s pipeline.
As at March 31, 2008, the Company’s cash and cash equivalents amounted to $9,116,406 compared to $11,279,030 as at December 31, 2007. The Company believes it has adequate resources to continue into the second quarter of 2009 based on its current cash and cash equivalent position.
As at March 31, 2008 the Company had 55,587,103 common shares, 5,761,146 stock options and 625,000 broker warrants outstanding.
Management’s Discussion and Analysis of the financial statements for the three-month period ended March 31, 2008 is available on SEDAR at www.sedar.com.
About GeneNews
--------------
GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews’ first product in development, ColonSentry(TM), is a convenient and patient-friendly blood-based test that can assess an individual’s current risk for colorectal cancer. For more information on GeneNews, visit www.genenews.com.
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company’s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
CONTACT: Dr. K. Wayne Marshall, President & CEO, (416) 650-0060 x 234,
wmarshall@genenews.com; James Smith, (416) 815-0070 x 229,
jsmith@equicomgroup.com
